What future improvements are planned for the Yenos nanopore platform?

OncuraKit and Yenos Analytical are continuously refining the platform. Future development directions include expanding the miRNA panel to additional cancer-associated markers, validating the test against additional cancer types beyond the current six primary targets, developing tissue-of-origin prediction capabilities (to help narrow follow-up testing), and potentially reducing turnaround time through workflow optimizations. Oxford Nanopore Technologies also continues to release improved flow cell generations (the R10 series has improved single-nucleotide resolution) that may benefit the Yenos quantification protocol. The core innovation — amplification-free, single-molecule miRNA counting — is protected by patents and provides a platform that can be extended to additional biomarkers without fundamental changes to the hardware.